Open Access<sup>177</sup>Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
Author(s) -
Katarzyna FrössBaron,
Ulrike GarskeRomán,
Staffan Welin,
Dan Granberg,
Barbro Eriksson,
Tanweera Shaheena Khan,
Mattias Sandström,
Anders Sundín
Publication year - 2020
Publication title -
neuroendocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.493
H-Index - 101
eISSN - 1423-0194
pISSN - 0028-3835
DOI - 10.1159/000506746
Subject(s) - radionuclide therapy , medicine , neuroendocrine tumors , chemotherapy , toxicity , bone marrow , gastroenterology , bone marrow suppression , oncology , urology
To retrospectively analyze toxicity, progression-free survival (PFS), overall survival (OS), and their determinants in patients with advanced pancreatic neuroendocrine tumors (PanNETs), previously pretreated with chemothe-r-apy, undergoing peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.